Takeda Pharmaceutical Co ADR (NYSE: TAK) on Monday, plunged -0.66% from the previous trading day, before settling in for the closing price of $13.62. Within the past 52 weeks, TAK’s price has moved between $12.57 and $15.08.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 11.56%. The company achieved an average annual earnings per share of -13.98%. With a float of $3.17 billion, this company’s outstanding shares have now reached $3.17 billion.
Let’s determine the extent of company efficiency that accounts for 49281 employees. In terms of profitability, gross margin is 62.47%, operating margin of 14.14%, and the pretax margin is 5.85%.
Takeda Pharmaceutical Co ADR (TAK) Breakdown of a Key Holders of the stock
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Takeda Pharmaceutical Co ADR is 0.02%, while institutional ownership is 5.17%. The most recent insider transaction that took place on Aug 23 ’24, was worth 284,951. Before that another transaction happened on Jan 24 ’24, when Company’s 10% Owner sold 3,703,703 for $8.10, making the entire transaction worth $29,999,994. This insider now owns 3,755,583 shares in total.
Takeda Pharmaceutical Co ADR (TAK) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -13.98% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 33.34% during the next five years compared to -12.87% drop over the previous five years of trading.
Takeda Pharmaceutical Co ADR (NYSE: TAK) Trading Performance Indicators
Takeda Pharmaceutical Co ADR (TAK) is currently performing well based on its current performance indicators. A quick ratio of 0.77 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.42. Likewise, its price to free cash flow for the trailing twelve months is 10.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.60, a number that is poised to hit 0.23 in the next quarter and is forecasted to reach 0.45 in one year’s time.
Technical Analysis of Takeda Pharmaceutical Co ADR (TAK)
Looking closely at Takeda Pharmaceutical Co ADR (NYSE: TAK), its last 5-days average volume was 2.21 million, which is a jump from its year-to-date volume of 1.84 million. As of the previous 9 days, the stock’s Stochastic %D was 16.56%. Additionally, its Average True Range was 0.18.
During the past 100 days, Takeda Pharmaceutical Co ADR’s (TAK) raw stochastic average was set at 27.57%, which indicates a significant increase from 9.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 15.77% in the past 14 days, which was lower than the 17.44% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.22, while its 200-day Moving Average is $13.90. However, in the short run, Takeda Pharmaceutical Co ADR’s stock first resistance to watch stands at $13.60. Second resistance stands at $13.68. The third major resistance level sits at $13.71. If the price goes on to break the first support level at $13.49, it is likely to go to the next support level at $13.46. Now, if the price goes above the second support level, the third support stands at $13.38.
Takeda Pharmaceutical Co ADR (NYSE: TAK) Key Stats
Market capitalization of the company is 42.90 billion based on 3,181,875K outstanding shares. Right now, sales total 29,420 M and income totals 994,060 K. The company made 7,904 M in profit during its latest quarter, and 618,620 K in sales during its previous quarter.
